Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Journal of Clinical Oncology · 10.01.2026 · 44 (2) · 103-116
DOI: 10.1200/jco-25-01210 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2026. Verfasst von Philipp Harter und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department for Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany. Hauptthemen laut MEDLINE: Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Ovarian Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE To evaluate atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for recurrent ovarian cancer. METHODS The double-blind randomized phase III AGO-OVAR 2.29/ENGOT-ov34 trial (ClinicalTrials.gov identifier: NCT03353831 ) enrolled patients with first or second relapse of ovarian cancer ≤6 months after completing platinum-based chemotherapy (or third relapse regardless of treatment-free interval). PD-L1 status was tested centrally (VENTANA SP142 assay) in recent (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department for Gynecology and Gynecologic Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
- Philipps-University of Marburg, Marburg, Germany.
- AGO Study Group, Wiesbaden, Germany.
- Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
- Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
- GEICO, Madrid, Spain.
ORCID-Profile: Philipp Harter, Frederik Marmé, Andrés Redondo, Kristina Lindemann, Christian Marth, Isabelle Ray-Coquard, Carmen Garcia-Duran, Florian Heitz, J Alejandro Pérez-Fidalgo, Ahmed El-Balat, Frédéric Selle, Ignacio Romero, Pauline Wimberger, Philippe Follana, Beatriz Pardo, Florence Joly, Lydia Gaba, Annette Hasenburg
Zitieren
APA
Harter, P., Marmé, F., Redondo, A., Reuss, A., Lindemann, K., Kurzeder, C., Van Nieuwenhuysen, E., Marth, C., Pietzner, K., Ray-Coquard, I., Garcia-Duran, C., Jonuskiene, G., Heitz, F., Béllier, C., Pérez-Fidalgo, J. A., El-Balat, A., Selle, F., Romero, I., Wimberger, P., …, & Pautier, P. (2026). Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. Journal of Clinical Oncology, 44(2), 103-116. https://doi.org/10.1200/jco-25-01210
Vancouver
Harter P, Marmé F, Redondo A, Reuss A, Lindemann K, Kurzeder C, et al. Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. Journal of Clinical Oncology. 2026;44(2):103-116. doi:10.1200/jco-25-01210
BibTeX
@article{Harter2026,
author = {Harter, Philipp and Marmé, Frederik and Redondo, Andrés and Reuss, Alexander and Lindemann, Kristina and Kurzeder, Christian and Van Nieuwenhuysen, Els and Marth, Christian and Pietzner, Klaus and Ray-Coquard, Isabelle and Garcia-Duran, Carmen and Jonuskiene, Goda and Heitz, Florian and Béllier, Charlotte and Pérez-Fidalgo, J Alejandro and El-Balat, Ahmed and Selle, Frédéric and Romero, Ignacio and Wimberger, Pauline and Follana, Philippe and Pardo, Beatriz and de Gregorio, Nikolaus and Joly, Florence and Gaba, Lydia and Burges, Alexander and Fabbro, Michel and Hasenburg, Annette and Fehm, Tanja and Schmalfeldt, Barbara and Pautier, Patricia},
title = {Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {2},
pages = {103--116},
doi = {10.1200/jco-25-01210}
}
EUVIMED